相关实验视频
Updated: May 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
联合奥米帕利西布和MAPK抑制抑制PDAC生长
Bailey A Bye1, Jarrid L Jack1, Alexandra Pierce1
1Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA.
用Omipalisib和Trametinib针对PI3K和MAPK通路显示出胰腺管腺癌 (PDAC) 治疗的前景. 这种组合疗法有效地抑制了瘤生长,并在临床前模型中改善了生存率.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 胰腺管道腺癌 (PDAC) 具有KRAS突变的特征,但针对KRAS或MAPK通路因子的治疗成功有限.
- 克拉斯影响MAPK和PI3K-AKT信号通路,这表明双通道向作为治疗策略.
研究的目的:
- 为了研究PI3K路径抑制剂Omipalisib与MAPK路径抑制剂Trametinib或SHP099结合用于PDAC治疗的疗效.
- 在临床前PDAC模型中评估PI3K-AKT和MAPK信号通路的联合抑制.
主要方法:
- 使用西方斑点分析来评估途径抑制 (pERK,pAKT).
- 对PDAC细胞系进行了体外研究,以评估增殖,殖民地形成和迁移.
- 在PDAC的小鼠模型中进行了使用口服的体内研究.
主要成果:
- 组合疗法 (奥米帕利西布/特拉美提尼布和奥米帕利西布/SHP099) 在体外表现优于单个治疗.
- 与Omipalisib/SHP099或单一疗法相比,Omipalisib/Trametinib在PDAC小鼠模型中显示出在减少瘤生长和延长存活时间方面更高的疗效.
结论:
- 双重准PI3K和MAPK通路是胰腺癌的可行策略.
- 奥米帕利西布和特拉美替尼布的组合值得进一步研究,作为一种潜在的PDAC治疗.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Abnormal Proliferation
MAPK Signaling Cascades